Allergy Thera. Share News (AGY)

Allergy Therapeutics Reports Profits, Revenues For Year To End-September

LONDON (Alliance News) - Allergy Therapeutics PLC Wednesday reported revenues of GBP40.5 million and a profit of GBP890,000 for the 12 months to September 30, 2013. The company's financial year runs until the end of June, but it has provided additional figures for the year to end-September

Allergy Therapeutics gets green light for hay fever study in Canada

Speciality pharmaceuticals firm Allergy Therapeutics has received the approval from the Canadian health regulators to submit a full clinical trial application for a new study of its hay fever vaccine. Following on from successful discussions held with the US Food and Drug Administration previously,

Allergy Therapeutics' Hay Fever CTA Approved By Health Canada

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday that the Canadian health authority has approved its proposal to submit a full clinical trial application for an efficacy study for Pollinex Quattro Grass MATA MPL (0.5ml). The speciality pharma firm said its proposal for a new

Allergy Therapeutics Says Positive Ragweed Allergy Treatment Published

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that results from its Phase IIb clinical trial of its Pollinex Quattro ragweed allergy treatment have been published in the Journal of Allergy and Clinical Immunology. The trial showed that the treatment was safe and effective in

Allergy Therapeutics Revenues Up 16%, Appoints New R&D Director

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Allergy Therapeutics boosts sales, gains market share

Allergy vaccine developer Allergy Therapeutics reported higher sales and revenue since July and said it was gaining share in all its main markets. The group said net revenues rose 16% in the first four months of this financial year against the same period last year while gross sales at constant cur

Allergy Therapeutics Hit By Challenging Conditions As Profit Declines

Monday broker round-up

AEC Education: WH Ireland places both its target price (prev.: 11p) and its recommendation under review. Aggreko: Citi reduces target price from 2100p to 2000p leaving its buy recommendation unaltered. Allergy Therapeutics: Panmure Gordon lowers target price from 18p to 16p, while keeping its buy

Allergy Therapeutics ends contract with Lincoln Medical

Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK. The pharmaceutical company said Lincoln Medical undertook a voluntary recall of all unexpired units of Apapen, an adrenali

Chamberlin Chairman invests 75k

Castings and engineering group Chamberlin announced on Monday that its Chairman has topped up his stake in the company twice over the couple of weeks. Keith Butler-Wheelhouse acquired a total of 44,500 Chamberlin ordinary shares through his family trust, BW Family Limited (BWFL), representing 0.56%

Shanks Chairman buys shares as profits fall

The Chairman of Shanks Group, the FTSE 250 waste management firm, has bought 60,000 shares in the firm following the company's announcement that half year profits fell by 29 per cent. Chairman Adrian Auer purchased the shares at 82.93p each for a total of £49,758. On Thursday the company revealed

Small caps round-up: Allergy, XCAP, Totally...

Allergy Therapeutics, a specialist pharmaceutical company focused on allergy vaccination, has welcomed the Food and Drugs Association's decision to lift the clinical hold on the company's grass pollen allergy vaccine clinical development programme, with immediate effect. Allergy has gained approval